tiprankstipranks
Advertisement
Advertisement

PTGX Stock Latest News

Protagonist price target raised to $110 from $107 at Leerink
The FlyProtagonist price target raised to $110 from $107 at Leerink
18d ago
PTGX
Protagonist Therapeutics price target raised to $120 from $112 at Citizens
PremiumThe Fly
Protagonist Therapeutics price target raised to $120 from $112 at Citizens
18d ago
PTGX
Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
PremiumThe Fly
Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
18d ago
PTGX
Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
PremiumThe Fly
Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
18d ago
PTGX
Protagonist Therapeutics price target raised to $125 from $115 at Citi
PremiumThe Fly
Protagonist Therapeutics price target raised to $125 from $115 at Citi
18d ago
PTGX
Protagonist Therapeutics price target raised to $119 from $113 at Barclays
PremiumThe FlyProtagonist Therapeutics price target raised to $119 from $113 at Barclays
18d ago
PTGX
Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
Premium
The Fly
Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
19d ago
PTGX
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
Premium
Ratings
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
19d ago
PTGX
Icotyde label upside surprise for Protagonist, says H.C. Wainwright
PremiumThe Fly
Icotyde label upside surprise for Protagonist, says H.C. Wainwright
19d ago
JNJ
PTGX
Protagonist announces Johnson & Johnson received approval for ICOTYDE
PremiumThe Fly
Protagonist announces Johnson & Johnson received approval for ICOTYDE
19d ago
JNJ
PTGX
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
PremiumTipRanks Newswire
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
1M ago
AZN
IBO
Protagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs
PremiumThe Fly
Protagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs
1M ago
PTGX
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
PremiumThe FlyProtagonist Therapeutics price target raised to $100 from $86 at Wedbush
1M ago
TAK
PTGX
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
Premium
The Fly
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
1M ago
TAK
PTGX
Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan
Premium
The Fly
Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan
1M ago
PTGX
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
PremiumCompany Announcements
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
1M ago
PTGX
Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen
PremiumThe Fly
Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen
1M ago
PTGX
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
PremiumRatings
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
1M ago
PTGX
Protagonist Therapeutics price target raised to $112 from $102 at Citizens
PremiumThe Fly
Protagonist Therapeutics price target raised to $112 from $102 at Citizens
1M ago
PTGX
Protagonist Therapeutics price target raised to $113 from $108 at Barclays
PremiumThe FlyProtagonist Therapeutics price target raised to $113 from $108 at Barclays
1M ago
PTGX
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
Premium
Ratings
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
1M ago
PTGX
Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright
Premium
The Fly
Protagonist Therapeutics price target raised to $117 from $80 at H.C. Wainwright
2M ago
PTGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >